drugset / Trial / NCT04430933

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

NCT04430933

Phase 1/2 Withdrawn NextCure, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy

Timeline

Start
2021-12-06
Primary completion
2022-06-30
Completion
2022-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NC318 Monoclonal antibody Intravenous
Background Carboplatin Small molecule
Background Docetaxel Small molecule
Background Paclitaxel Small molecule
Background Pemetrexed Small molecule